About Probe Scientific

Probe Scientific develops innovative products to solve clinical problems and improve healthcare outcomes. With a substantial product pipeline based on our proprietary technologies, we are seeking to commercialise this range to benefit both clinicians and the wider community.

The first validation of our technology has been in continuous glucose monitoring in critical care, with a number of commercial partnerships under way. Many other applications of Probe’s core technology are being developed for exploitation.

Having grown steadily since its origins, Probe Scientific is now able to sustain the development of new applications from income generated from licensing activities. From time to time additional investment is used to speed up specific applications and maximise the best opportunities.

Probe Scientific Ltd is a private company with facilities in Bedfordshire and the West Midlands, UK.

Management Team

Neil@2xLinkedIn profile

Neil Smith BSc

CEO

Neil has extensive senior general management and marketing experience in the international Medical Device industry, together with considerable expertise in launching new products and therapies in international markets. Neil’s degree in Chemistry from Aston University in the UK is complemented by Business School training from INSEAD (CEDEP) in France. Prior to joining Probe, Neil was CEO of Healthline Products Ltd; he gained experience in dialysis and IV therapy, and held posts at companies including Baxter and Kendall McGaw.Read more

Mark@2xLinkedIn profile

Mark O’Connell MIBiol, CBiol (London), PhD (London)

Co-founder / Technical Director

As an Analyst at the ‘Poisons Unit’, Guy’s Hospital, London, from 1980 to 1986, Mark recognised the problems associated with diagnostics using conventional blood sampling. While studying for his PhD at the Institute of Neurology, London, he began using the then novel technique of brain microdialysis. As Principal Biochemist at the National Hospital for Neurology and Neurosurgery, London from 1991 to 1995, Mark pioneered the application of clinical microdialysis. In 1993 he began using intravenous microdialysis for drug monitoring in patients, publishing this 'proof-of-principle' work in the British Journal of Clinical Pharmacology. As Senior Clinical Scientist at Addenbrooke’s Hospital, University of Cambridge until 2005, his knowledge and expertise helped establish Cambridge as a leading centre in the field of microdialysis. Mark is an international speaker and author of over 50 scientific and medical papers.Read more

paul-jenkinson

Paul Jenkinson BSc, ACA, MSI

Finance Director

Paul qualified as a Chartered Accountant with Deloitte & Touche in 1994. Moving into corporate finance he spent three years raising funds for early-stage technology companies and a further two years working on larger buy-outs, mergers and acquisitions and corporate disposals for private and public companies. In 1999 Paul became Finance Director of a software company and subsequently floated it on OFEX. In 2001 he joined an AIM quoted software company as Finance Director and from 2002 was Finance Director for a number of venture capital backed companies. Paul joined the board of Probe Scientific as Finance Director in 2005.Read more

UntitledLinkedIn profile

George Zajicek

Chairman

George is a pharmacist who started his industrial career in pharmaceuticals with Merck Sharp & Dohme, moving to Boehringer Ingelheim where he headed up the Regulatory Group and was involved in new business development. As Head of Product Control with Unipath he helped launch the ground-breaking Clearblue pregnancy test and pioneered work targeting radioisotope-labelled monoclonal antibodies against certain cancers. George has also been Marketing Director of Shield Diagnostics, Business Development Director with Axis-Shield plc and Chairman of Platform Diagnostics. He is the founding Chairman of BIVDA and the current Chairman of DDS, a clinical trial research organisation based at Ninewells Hospital, Dundee. He has also been involved in much government interaction, latterly including the Life Sciences Industry Advisory Group for Scotland.Read more

dad's buisness photo

Denis Lonergan

Co-founder / Non-Executive Director

Denis is a co-founder of Probe Scientific Limited and provided the early funding for the company. In 1992 he founded Cornel Associates, a consultancy that offers advice and early-stage funding to a number of biotech and medical device companies, both private and listed.Read more

rod-rustonLinkedIn profile

Rod Ruston

Regulatory & Quality Assurance

Rod is a highly experienced regulatory specialist. Rod and his company, Priory Analysts, have been providing regulatory assistance to Probe since our first manufacturing project.

daniel-carneyLinkedIn profile

Dan Carney

Researcher

safa-iram

Saf Iram

Administrator

Board of Directors

George Zajicek

Chairman

George is a pharmacist who started his industrial career in pharmaceuticals with Merck Sharp & Dohme, moving to Boehringer Ingelheim where he headed up the Regulatory Group and was involved in new business development. As Head of Product Control with Unipath he helped launch the ground-breaking Clearblue pregnancy test and pioneered work targeting radioisotope-labelled monoclonal antibodies against certain cancers. George has also been Marketing Director of Shield Diagnostics, Business Development Director with Axis-Shield plc and Chairman of Platform Diagnostics. He is the founding Chairman of BIVDA and the current Chairman of DDS, a clinical trial research organisation based at Ninewells Hospital, Dundee. He has also been involved in much government interaction, latterly including the Life Sciences Industry Advisory Group for Scotland.Read more

Neil Smith BSc

CEO

Neil has extensive senior general management and marketing experience in the international Medical Device industry, together with considerable expertise in launching new products and therapies in international markets.

Mark O’Connell MIBiol, CBiol (London), PhD (London)

Co-founder / Technical Director

As a clinical scientist for over 27 years Mark has considerable experience of diagnostic patient monitoring and understands unmet clinical needs. In the early 1990s he set about improving conventional practice and subsequently patented technology to revolutionise this field. Together with Denis Lonergan, Mark founded Probe to deliver novel tools enabling healthcare professionals to improve patient management and to reduce care costs. Mark received management training while working for the NHS, and was a team member responsible for introducing healthcare ICT systems into the National Hospital for Neurology and Neurosurgery, London. He beat seven other finalists to win the Business Launch Award at the Cambridge Enterprise Conference, 2003.Read more

Paul Jenkinson BSc, ACA, MSI

Finance Director

Paul qualified in 1994 as a Chartered Accountant with Deloitte & Touche. Moving into corporate finance he spent three years raising funds for early-stage technology companies and a further two years working on larger buy-outs, mergers and acquisitions and corporate disposals for private and public companies. In 1999 Paul became Finance Director of a software company and subsequently floated it on OFEX. In 2001 he joined an AIM quoted software company as Finance Director and from 2002 was Finance Director for a number of venture capital backed companies. Paul joined the board of Probe Scientific as Finance Director in 2005.Read more

Denis Lonergan

Co-founder / Non-Executive Director

Denis is a co-founder of Probe Scientific Limited and provided the early funding for the company. In 1992 he founded Cornel Associates, a consultancy that offers advice and early-stage funding to a number of biotech and medical device companies, both private and listed.Read more

Investor info

Probe Scientific is a private UK-based company with a number of institutional and private investors. Probe Scientific has a wide investor base and we seek to work in partnership with our shareholders and other stakeholders. We also have as shareholders a number of very important Business Angels who have continued to support the company for many years. We like to keep our shareholders well informed of our progress technically, commercially and financially. Our institutional investors are:

Catapult Ventures

Catapult Ventures is a venture capital fund manager and operates a number of discrete venture capital funds on behalf of a range of public and private investors. Catapult’s experienced investment professionals have been providing equity capital to SMEs since 1999, acting as a long term, trusted partner and supportive investor to more than 70 companies.Read more

Nesta

NESTA is the National Endowment for Science, Technology and the Arts – a unique and independent body with a mission to make the UK more innovative. NESTA invests in early-stage companies, informs and shapes policy, and delivers practical programmes that inspire others to solve the big challenges of the future.Read more

SBA

The Sophia Business Angels club is a select group of international serial entrepreneurs and senior managers coming together once a month in the European high-tech capital of Sophia Antipolis, France.Read more